Spruce Biosciences Joins the Russell 3000® Index

About this update from Spruce Biosciences, Inc.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has been added as a member of the Russell 3000® Index, effective with the opening of U.S. equity markets today, in connection with the 2026 Russell U.S. Indexes Reconstitution. The Russell 3000® Index measures the performance of the largest U.S.-listed companies based on total market capitalization and is periodically reconstituted by FTSE Russell. Companies included in the Russell 3000® Index are automatically included in the small-cap Russell 2000® Index. Both indexes are widely used by investment managers and institutional investors for both index-based and active investment strategies, and serve as benchmarks against which the performance of investment products is measured. “Our addition to the Russell 3000® Index reflects the progress we have made as a precommercial organization preparing for the potential U.S. FDA approval and launch of TA-ERT for MPS IIIB,” said Samir Gharib, President and Chief Financial Officer of Spruce Biosciences. “We believe inclusion in the index will enhance our visibility within the broader investment community, help broaden our shareholder base, and support trading liquidity as we advance toward a planned BLA submission of TA-ERT. We thank our shareholders for their continued support and remain focused on delivering value for the patients and families we serve.” About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. Spruce’s lead product candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is in late-stage development for the treatment of mucopolysaccharidoses type IIIB (MPS IIIB), or Sanfilippo Syndrome Type B, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube. Forward-Looking Statements Sta...

View stock analysis, news, and events for Spruce Biosciences, Inc.